<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study examined the neuroprotective effects and possible <z:e sem="disease" ids="C0235378,C0348754" disease_type="Disease or Syndrome;Injury or Poisoning" abbrv="">hepatotoxicity</z:e> of <z:chebi fb="0" ids="42255">(-)-epigallocatechin</z:chebi> <z:chebi fb="0" ids="16918">gallate</z:chebi> (<z:chebi fb="0" ids="4806">EGCG</z:chebi>) in a rat model of transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Male Sprague-Dawley rats (265-295 g) were treated with either 50 mg kg(-1) of <z:chebi fb="0" ids="4806">EGCG</z:chebi> or saline, i.p., immediately post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and every day thereafter, in a middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Sacrifice occurred 72 h post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> staining was used to quantify neuronal infarction </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0235378,C0348754" disease_type="Disease or Syndrome;Injury or Poisoning" abbrv="">Hepatotoxicity</z:e> was determined by taking blood samples for plasma alanine aminotransferase (ALT) activity </plain></SENT>
<SENT sid="4" pm="."><plain>Spleen, kidney, liver and testes wet weights were also recorded </plain></SENT>
<SENT sid="5" pm="."><plain>Total <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was significantly (P&lt;0.05) reduced in the <z:chebi fb="0" ids="4806">EGCG</z:chebi>-treated group as compared to controls </plain></SENT>
<SENT sid="6" pm="."><plain>Analysis of the mean <z:mpath ids='MPATH_124'>infarct</z:mpath> area showed a significant (P&lt;0.05) decrease in slices 6 and 7 in the <z:chebi fb="0" ids="4806">EGCG</z:chebi>-treated group </plain></SENT>
<SENT sid="7" pm="."><plain>No significant differences were found in organ weights or ALT levels between treatment groups </plain></SENT>
<SENT sid="8" pm="."><plain>Our findings, in part, validate and extend previous observations illustrating that 50 mg kg(-1), i.p </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="4806">EGCG</z:chebi> is non-toxic and neuroprotective </plain></SENT>
<SENT sid="10" pm="."><plain>However, we also found that <z:chebi fb="0" ids="4806">EGCG</z:chebi> treatment appreciably increased (&gt;50%) the number of animals that developed an <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>We therefore conclude that 50 mg kg(-1) <z:chebi fb="0" ids="4806">EGCG</z:chebi> is not a viable intervention for the <z:hpo ids='HP_0011009'>acute</z:hpo> treatment of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, as it is likely to increase the risk of intracerebral hemorrhaging </plain></SENT>
</text></document>